In the TME of MC38 tumor‐bearing mice, treatment with QTPlus‐AM21 showed increased CD45+ tumor‐infiltrated immune cells (Figure 9A,B) and F4/80+ CD86+ M1 populations (Figure 9C,D). This evidence concerns the gene CD86 and neoplasm.